Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12551898 | 0.93 | CYP3A4 (0.41) | PSIP1CYP3A4KCNH2NR1I2 | |
| SCHEMBL12533605 | 0.91 | PSIP1 (0.39) | PSIP1CYP3A4KCNH2NR1I2 | |
| SCHEMBL12533738 | 0.91 | PSIP1 (0.39) | PSIP1CYP3A4KCNH2NR1I2 | |
| SCHEMBL12533756 | 0.91 | CYP3A4 (0.32) | PSIP1CYP3A4 | |
| SCHEMBL14405288 | 0.91 | PSIP1 (0.39) | PSIP1CYP3A4KCNH2NR1I2 | |
| SCHEMBL12551893 | 0.84 | PSIP1 (0.40) | PSIP1CYP3A4KCNH2NR1I2 | |
| SCHEMBL12533607 | 0.82 | CYP3A4 (0.32) | PSIP1CYP3A4 | |
| SCHEMBL13862933 | 0.82 | CYP3A4 (0.32) | PSIP1CYP3A4 | |
| SCHEMBL12533743 | 0.82 | CYP3A4 (0.32) | PSIP1CYP3A4 | |
| SCHEMBL12551891 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2574610-A1 | Inhibitors of human immonodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2013-04-03 | — | — | EP | disclosed |
| EP-2220095-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES INC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-7956068-B2 | Inhibitors of human immunodeficiency virus replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| US-7956068-B2 | Inhibitors of human immunodeficiency virus replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009062288-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | CCNY, RTF2, POLR2E | PSIP1 1240/4885CYP3A4 786/4885KCNH2 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.